Thomas Jefferson University

Jefferson Digital Commons
Department of Neurology Faculty Papers

Department of Neurology

5-1-2006

Light during darkness and cancer: relationships in circadian
photoreception and tumor biology
Samar A. Jasser
Thomas Jefferson University

David E. Blask
Basset Research Institute

George C. Brainard
Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp
Part of the Neurology Commons

Let us know how access to this document benefits you
Recommended Citation
Jasser, Samar A.; Blask, David E.; and Brainard, George C., "Light during darkness and cancer:
relationships in circadian photoreception and tumor biology" (2006). Department of Neurology
Faculty Papers. Paper 1.
https://jdc.jefferson.edu/neurologyfp/1
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Light During Darkness and Cancer: Relationships in
Circadian Photoreception and Tumor Biology
Samar A. Jasser1 , David E. Blask2 and George C. Brainard1
(1) Department of Neurology, Light Research Program, Thomas Jefferson University,
1025 Walnut Street, Suite 507, PA 19107 Philadelphia, USA
(2) Laboratory of Chrono-Neuroendocrine Oncology, Bassett Research Institute, NY,
USA
Corresponding author:
Samar A. Jasser
Email: samar.jasser@jefferson.edu
Phone: 215-955-9409
Fax: 215-923-7588

Abstract
The relationship between circadian phototransduction and circadian-regulated processes
is poorly understood. Melatonin, commonly a circadian phase marker, may play a direct
role in a myriad of physiologic processes. The circadian rhythm for pineal melatonin
secretion is regulated by the hypothalamic suprachiasmatic nucleus (SCN). Its neural
source of light input is a unique subset of intrinsically photosensitive retinal ganglion
cells expressing melanopsin, the primary circadian photopigment in rodents and primates.
Action spectra of melatonin suppression by light have shown that light in the 446–
477 nm range, distinct from the visual system’s peak sensitivity, is optimal for
stimulating the human circadian system. Breast cancer is the oncological disease entity
whose relationship to circadian rhythm fluctuations has perhaps been most extensively
studied. Empirical data has increasingly supported the hypothesis that higher risk of
breast cancer in industrialized countries is partly due to increased exposure to light at
night. Studies of tumor biology implicate melatonin as a potential mediator of this effect.
Yet, causality between lifestyle factors and circadian tumor biology remains elusive and
likely reflects significant variability with physiologic context. Continued rigorous
empirical inquiry into the physiology and clinical implications of these habitual,
integrated aspects of life is highly warranted at this time.

Introduction
The relationship between circadian phototransduction, endogenous melatonin levels,
endocrine hormone physiology, and the myriad of normal and pathological circadianregulated processes is far from being fully illuminated1,2. Many mutually consistent
associations have been made between the light exposure history of an organism, circadian
clock gene regulation, melatonin secretion, and the dysregulation of cell biology in
cancer1,3, but the specifics of these relationships are still poorly understood. It is well
established that light of sufficient intensity has an acute suppressive effect upon the
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secretion of melatonin from the human pineal gland and that this suppression directly
reflects the action of a non-visual photoreceptive system in circadian phototransduction4.
The health implications of this suppressive potential of light upon melatonin, however,
have only recently begun to be addressed.
Melatonin has been used frequently as a scientific marker of circadian phase5, or a
biochemical marker of darkness6. Nevertheless, there is accumulating evidence that
melatonin, as related to sleep/wake cycles and circadian physiology in general, may have
a more direct role in several physiologic processes, spanning the fields of psychiatry,
psychoneuroimmunology, oncology, and reproductive endocrinology7. For example,
melatonin and circadian disturbance have been implicated in the pathophysiology of
Seasonal Affective Disorder (SAD)7-10, and light therapy has been shown to be an
effective treatment for this syndrome11-13. Low serum melatonin concentrations and
urinary metabolite levels have also been found in women with estrogen-receptor positive
breast cancer and men with prostate cancer14-16. More specifically, melatonin has been
shown to have antiproliferative effects on neoplasms of several tissue types in vitro and
in vivo 17,18, to possess related antioxidant effects 7, 19-21, and to have immunostimulatory
effects7,22.
Relatedly, some evidence suggests that alterations to endogenous reproductive hormone
physiology, particularly the menstrual cycle length, may be a common pathway through
which disruptions to melatonin and circadian rhythms affect breast cancer development
and progression23. Animal studies have demonstrated that melatonin can, via influence
upon gonadotropin-releasing hormone (GnRH) release in the hypothalamic–pituitary
axis, affect gonadotropin (LH and FSH) release from the pituitary gland and, in turn,
gonadal function. There is some indirect evidence in humans consistent with these
findings, though the implications are still quite unclear21,24. For example, a correlation
has been made between the stage of breast cancer and inversely proportional changes in
nocturnal melatonin levels in breast cancer patients15. One study showed that the addition
of melatonin to the traditional pharmacologic management of metastatic breast cancer
appeared to slow disease progression21,25. Consistent findings have been shown in other
cancer types21,26-27. Additionally, the oncostatic action of melatonin on human breast
cancer has been linked to estrogen response21,28, with interactions occurring between
melatonin and estradiol to influence breast cancer cell development21,29. This relationship
between the hormones does not appear to be reciprocal, however, as it has been shown
that the menstrual cycle phase and reproductive hormone status does not affect a
woman’s melatonin secretion7 or sensitivity to melatonin suppression by light30.
The complexity and importance of the interactions between light, the circadian system,
and subsequent disturbances in hormone physiology and cancer is highlighted by the
body of scientific evidence surrounding the relationship between light and breast cancer.
Tissue-specific circadian clock organization in both normal and neoplastic proliferative
tissue has the potential to accelerate tumor growth31. Similarly, the direction of melatonin
rhythm entrainment to light stimuli as an advance or delay of the nighttime peak, is
dependent upon the circadian time of the endogenous rhythm upon which the stimulus is
superimposed32. This plasticity of response, however, like every other dynamic
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physiologic process that occurs within the context of changing internal and external
biological environments, is likely compounded by unique variations in response at
different points along the pathways of light transmission. The concept of tissue-specific
circadian programming via varied expression of clock genes is one mechanism of this
plasticity, for example1. Regardless, any effort to begin clarifying this complexity is
dependent upon an understanding of the incipient alterations that occur in the biological
response to light, specifically, in circadian phototransduction.

The first dominos in the biological effect of light
The circadian rhythm for melatonin secretion is regulated by the endogenously generated
rhythm of the hypothalamic suprachiasmatic nuclei (SCN), via an indirect multi-synaptic
pathway to the pineal gland. This intrinsic rhythm is, in turn, synchronized by light input
from the environment to the SCN via the direct projections of the retinohypothalamic
tract (RHT)33. A simplified diagram of the elements of this circuitry is shown in Figure 1.
The source of these projections to the SCN is a unique subset of intrinsically
photosensitive retinal ganglion cells (ipRGCs)34-37, and these intrinsically photosensitive
ganglion cells have been shown to be in the same subset of retinal cells that express
melanopsin38-39.
Initially, the search for an alternate circadian photoreceptor included both opsin-based
molecules such as RPE-retinal G protein-coupled receptor, peropsin, encephalopsin, and
melanopsin as well as non-opsin molecules like cryptochrome40. Cryptochrome was an
early candidate as a nonvisual photoreceptor in mammals since it plays a central role in
circadian photoreception in lower species41. Current evidence, however, suggests that the
two cryptochrome homologs found in the inner retina of mammals are not strictly
required for mammalian circadian phototransduction, but may have an accessory function
in inner retinal phototransduction42.
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Fig. 1 Light influences melatonin secretion from the pineal gland via a multi-synaptic, indirect
neural circuit. Light enters the eye through the pupillary aperture, stimulates the retina and sends
its signal to the circadian pacemaker, the SCN, via a direct retinohypothalamic projection (RHT).
Not shown here is the accessory connection between an integrating center in the thalamus, the
intergeniculate leaflet (IGL), and the SCN. The IGL provides a second neural pathway for light to
influence the circadian pacemaker. From the SCN, impulses travel to the pineal gland by first
synapsing at the paraventricular nucleus of the hypothalamus, descending to synapse in the
interomediolateral cell column (IMLCC) of the upper thoracic spinal cord, projecting to the
superior cervical ganglion, and finally ascending along the cerebral vasculature to its final synapse
at the pineal gland33

Recent evidence has confirmed that melanopsin is a primary photopigment mediating
circadian phototransduction in rodents and primates43-46. Specifically, cells which are
inherently incapable of photoreception were rendered photoreceptive after heterologous
expression of human melanopsin43-46. It has been shown that the ipRGCs in rats and
monkeys will depolarize in response to light with a peak spectral sensitivity around
480 nm, even with the blockage of synaptic input from rods and cones34. Furthermore,
studies in rodents with retinal degeneration have indicated that neither the rod nor cone
photoreceptors necessarily participate in circadian responses to light, including melatonin
suppression and photoperiodic response47-49. Thus, both the anatomical distribution and
physiologic profile of melanopsin indicate that this photoreceptive system is a
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fundamental gateway for influencing the SCN’s perception of light stimuli in the
environment, and consequently, the responses of many dependent biological processes.
The acute suppression of plasma melatonin by light is a well-defined means of measuring
the sensitivity of this non-visual photoreceptive system4,50, regardless of any downstream
effects of the synthesized melatonin. Action spectra of melatonin suppression by light in
healthy human subjects have shown that light in the 446–477 nm range is optimal for
stimulating the circadian system and eliciting this suppression response51-52. This peak is
distinct from the peak sensitivity of the three-cone photopic visual system, as well as
each of the individual rods and cones for vision51-53. A study demonstrating that 460 nm
monochromatic light is significantly more potent than 555 nm for phase-shifting the
circadian pacemaker of healthy humans offers specific evidence to show that the peak
sensitivity of the human circadian pacemaker is distinct from that of the classical threecone system for photopic vision54. Figure 2 illustrates the two distinct photosensitivity
inputs for vision and melatonin suppression.

Fig. 2 Comparison of action spectra for the novel, melanopsin-based circadian photoreceptive
system and the photopic, classical cone photoreceptors. The circadian action spectrum peaks in the
446–477 nm range, versus a 555 nm peak for the three cone visual system

Of note, however, it is apparent that the rods and cones, though not essential to the
circadian response to light stimuli, appear to have a role in circadian photoreception
under normal physiologic conditions. For example, retinally degenerate mice, while still
maintaining the capacity for circadian photoreception and response to light, have a
spectral sensitivity for circadian phase-shifting that is different from wild-type mice with
normal functioning rods and cones55. There is also a residual phase shifting response in
melanopsin genetic knock-out mice which suggests an alternate or redundant means for
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light input to the SCN56. Studies in transgenic rodent models suggest that rod and cone
photoreceptors have the capacity to transduce light for circadian regulation57. The extent
to which these basic molecular findings in other mammals can be carried over in
application to humans is still unknown, however the evidence to date in humans and nonhuman primates suggests there is a high level of correlation39,46. For example, it has been
shown in humans that there is a bidirectional, mutual input potential between the novel,
non-classical opsin-based photopigment and the classical rod-cone photoreceptors,
where, under normal conditions, the novel circadian photopigment has a measurable role
in rod and cone adaptation to light over time58. The SCN, itself, is also capable of
receiving integrated neural information from the intergeniculate leaflet (IGL) of the
thalamus, which itself receives retinal projections from the rod and cone visual system59.
Thus, light has at least two neural pathways for stimulating the SCN in the process of
entrainment, phase-shifting, or melatonin suppression. The light-induced regulation of
melatonin or the broader circadian system can, in turn, potentially alter other physiologic
processes downstream to a degree of magnitude which is still unknown.
The distinction between visual and circadian photoreception has been demonstrated on an
empiric level as well. Blind persons who have no residual perception of light stimuli have
nonetheless shown a melatonin suppression and circadian phase-shifting responses to
bright light exposure60-61. Similarly, colorblind individuals appear to maintain this lightinduced melatonin suppression62. The epidemiologic evidence showing a significantly
decreased risk of breast cancer in women with profound bilateral blindness as compared
with normally sighted women63-64 suggests a correlation between these findings and the
oncostatic properties of melatonin in the setting of cancer. Also supporting the idea of
circadian melatonin regulation via a non-visual photoreceptive system as an endocrine
link between light and reproductive hormone disturbances is the finding that blindness in
human females is associated with an age of menarche that is earlier than normal and
proportional to the level of light perception loss65.
Finally, although less sensitive than the visual system, circadian photoreception appears
to be capable of responding to relatively low levels of light4,5,66-68. It has been shown in
laboratory animals that indirect light as dim as 0.2 lux (0.06 μW/cm2) has the capacity to
significantly suppress nocturnal plasma melatonin levels and consequently increase
hepatoma growth69-70. At the same time, however, circadian photoreception appears to
involve a still poorly characterized and complicated method of integration of light stimuli
over time by the photoreceptors themselves58, further downstream at the SCN71, and even
more broadly on a tissue-specific level1. More recently, specific molecular findings are
highly suggestive of melanopsin behaving more like an invertebrate opsin in nature than
a vertebrate opsin and acting more like a photopigment than a photoisomerase
influencing some other still-unknown opsin molecule58. The implications of these
findings are far-reaching with regard to questions of photoreceptor adaptation and
bleaching, for recent light history does appear to attenuate the response of subsequent
melatonin suppression by bright white light72-73. Yet this varied circadian photoreceptive
response throughout time cannot be accounted for by simple photon summation over the
period of observation54. Summarily, it appears that circadian photoreception has specific
spectral parameters for optimal response and a very low threshold for excitation, but
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these characteristics cannot be accurately considered in isolation from their
environmental, biological, and behavioral context.

Circadian light measurement
With such a distinct photoresponse profile, it has become increasingly apparent that
traditional means of light measurement do not suffice to provide an accurate point-intime measurement of light input to the mammalian circadian system. For more than
25 years, research surrounding human circadian physiology has primarily used a
photometric-based description and light measurement system5,74. The use of this
measurement perspective, however, implies that the human visual (rod and cone
photoreceptor) system is the primary system involved in circadian photoreception. A
series of recent human experiments employing standard photobiological techniques have
shown, specifically, that lux measurements are inappropriate for circadian,
neuroendocrine, and therapeutic purposes. Specifically, equal photon doses of shortwavelength monochromatic light evoke a stronger acute melatonin suppression
responses, circadian phase-shifts, core body temperature changes, subjective sleepiness,
heart rate, auditory reaction time, and auditory lapses in human subjects, when compared
with longer wavelength light at the peak of the photopic sensitivity curve51-54,75. The
importance of this distinction in light measurement is demonstrated by the finding that,
under optimum exposure conditions, as little as 5 lux of 460 nm light evokes an
equivalent phase shift (3 h phase delay) when compared with 10,000 lux white
fluorescent light54.
Thus, the characterization of light exposures for non-visual photobiological responses,
including melatonin suppression, circadian phase-shifting, and tumor growth, should
include radiometric quantification of irradiance and spectral power distribution76-77.
Furthermore, the implication of these findings for understanding the influence of various
lighting conditions upon subsequent tumor development in vivo is to highlight the need
for increased research conducted under conditions that emulate the daily photic
environment of humans.

The time of light
The circadian system’s sensitivity to light stimuli varies immensely with both the
circadian phase and the end effect being measured. It has been shown that practically all
normal proliferating tissues have been shown to undergo circadian variation in DNA
synthesis and mitotic index across a 24 h period, and similar variations appear to exist in
tumor tissues depending upon the type and stage of growth31,78. Furthermore, as indicated
in Figure 3, this tissue-specific rhythm is not necessarily directly reflective of broader,
overarching circadian rhythms regulated by the biological master clock in the SCN1.
Many anticancer agents have limiting cytotoxic effects on normal tissues that vary with
cell proliferative activity and cell cycle stage78. Thus, an understanding of the
characteristics of this circadian variation in response to a given light stimulus is highly
germane to clarifying the relationship between light and cancer. Gaining utility of this
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differential response of normal and neoplastic tissues to chemotherapy according to
circadian state has the potential to maximize chemotherapeutic efficacy while minimizing
toxicity. Advantages for circadian scheduling of chemotherapies have in fact already
been shown to diminish side effects and increase the maximum tolerated doses for
increased tumor response78.

Fig. 3 Cell growth and division follows a tissue-specific program that is influenced by, but not
homologous with, the SCN master clock rhythm. Solid arrows represent primary neural influence.
Dotted arrows represent secondary synaptic influence. Figure adapted from Hastings, et al.1
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Light exposure during darkness and breast cancer
Breast cancer is the oncological disease entity whose relationship to circadian rhythm
fluctuations has been brought most extensively to the attention of both clinical and basic
science research. It has been shown that otherwise healthy women who are chronically
subjected to nighttime shiftwork, and thus to light exposure at night, have a higher
incidence of breast cancer79-80. Epidemiologically, the World Health Organization
estimated in 1980 that half of all cancer in the world occurred in areas comprising onefifth of the world’s population, namely industrialized countries81. Thus, it has been
hypothesized that the increased risk of breast cancer in industrialized countries is due, in
part, to increased exposure to light at night, relative to unindustrialized countries who
have significantly fewer nightshift workers23,82-83.
Increasingly, published empirical data has been supporting this hypothesis. Melatonin has
been shown, at physiologic concentrations, to have a direct inhibitory effect on human
breast cancer cells in vitro21 and even more recently, in vivo18,84. It has also been
established that light of sufficient intensity at night has the capacity to acutely inhibit the
normal nocturnal rise in melatonin in humans4,21,85. This, in turn, would suggest that any
environmental exposure which results in a relative decrease in integrated melatonin levels
over time would consequently result in less oncostatic protection and a higher rate of
breast cancer development and/or proliferation. This theoretical construct is consistent
with epidemiologic findings80, as well as the melatonin-breast cancer hypothesis82. With
acute light-induced melatonin suppression, however, there is likely to be coincident
disruption of circadian phase and/or entrainment. Thus, it has not yet been determined if
light exposure at night is a risk specifically due to acute melatonin suppression, to
circadian disruption, or both.
The majority of studies have demonstrated a marked stimulatory effect of either
pinealectomy or constant light exposure on tumor development and growth21,86. In
general, following pinealectomy or exposure to constant bright light, not only do tumors
appear earlier, but a greater percentage of animals develop tumors and more tumors
develop per animal as compared to control animals maintained on an alternating 12 h
light:12 h dark cycle. Although constant light exposure seems to stimulate tumorigenesis
in the majority of investigations, clearly one-third of the studies conducted report either
inhibitory, mixed or no effects on the development of experimental cancer. Interestingly,
more consistent stimulatory actions of continuous illumination appear to occur with
respect to the growth of established tumors86. In rats bearing either tissue-isolated rat
liver cancer (i.e., hepatoma) or rat mammary cancer, constant bright light exposure (i.e.,
300 lux at eye level) for one week prior to tumor implantation and continuing thereafter,
completely suppresses the nocturnal, circadian rise in circulating melatonin levels, as
compared with L:D controls. Tumors appear much earlier as a result of constant light
exposure and their average daily growth rate accelerates by a factor of 2.5–6 times over
the average growth rate of tumors in the L:D control group. The marked increase in the
rates of tumor growth results from a substantial augmentation in the rate of rumor uptake
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of linoleic acid (LA) and its conversion to 13-hydroxyoctadecadienoic acid (13-HODE)
as a consequence of the suppression of the circadian melatonin signal69-70,87.
The ability of ocular light exposure to suppress pineal melatonin production depends on
the intensity, wavelength, duration, and timing of light. As important as the constant
bright light studies are, they address only one aspect of the intensity issue. Previous
studies have demonstrated that the exposure of rats to low intensity fluorescent light (i.e.,
0.2 lux at rodent eye level) during the dark phase for one week prior to the implantation
of tissue-isolated rat hepatomas, results in a nearly complete suppression of circulating
melatonin levels. Interestingly, the tumor growth rate, LA uptake, and metabolism to 13HODE are nearly as rapid as in constant light-exposed animals, indicating that low
intensity light-induced melatonin suppression during the dark phase is as effective as
constant light exposure in tumor growth and LA metabolism69-70. Even more recent
studies have examined the effects of different light intensities during darkness on
nocturnal circulating melatonin levels and the growth and LA metabolism of rat
hepatoma 7288CTC88. Exposure of tumor-bearing rats to fluorescent light intensities (at
rodent eye level) ranging from complete darkness to constant bright light (345 μW/cm2 or
∼840 lux) results in a dose-dependent suppression of melatonin levels with a concomitant
dose-related stimulation of tumor growth, LA uptake and 13-HODE production88. These
findings represent the first evidence that stimulation of tumor growth and metabolism is
dependent on the degree of the suppression of melatonin production that is, in turn,
dependent upon the intensity of light present during darkness. Studies are currently
examining fluence–response issues relative to melatonin suppression and the growth and
LA metabolism of human breast cancer xenografts in nude rats. Furthermore, other
ongoing studies are focusing on the role of the nocturnal, circadian melatonin signal, and
its suppression by light during darkness in human volunteers, on human breast cancer
xenograft growth and LA metabolism.
The light-melatonin-breast cancer hypothesis, with specific regard to human breast
carcinogenesis, has not been directly addressed until recently. This has been done using a
strain of athymic female rats in which human breast cancer xenografts grow quite well.
During a two week period following their transfer from a 12L:12D light:dark cycle (i.e.,
intact circadian melatonin signal) to constant 300 lux bright light (i.e., no nocturnal
melatonin signal), the average daily rate of tumor growth in constant light-exposed rats
increased by seven-fold in comparison to the tumor growth rate in animals remaining on
an L:D cycle. This accelerated rate of human breast cancer growth was initiated and
sustained as a result of increases in the rate of tumor uptake of LA and its metabolism to
13-HODE. This augmented rate of tumor LA uptake and metabolism resulted from
constant light-induced suppression of the circadian melatonin signal which normally
drives the inhibition of these processes during the dark phase84. This is the first
experimental evidence to date showing a link between inappropriate exposure to
continuous bright light and increased growth and fatty acid metabolism of human breast
cancer.
Thus, a better understanding of the photobiology underlying the effects of light upon
endogenous melatonin rhythm offers potential to further scientific understanding of the
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development and maintenance of oncologic processes. More specifically, the response of
this dynamic system to changes in light intensity, spectral quality, and varied light
exposure history is highly germane to gaining a better understanding of the potential
relationships between light exposure and cancer risk. Elucidating the underlying photic
input physiology to the pineal gland and subsequent melatonin regulation may provide a
common doorway to influence both normal neuroendocrine homeostasis as well as
oncological processes. Ultimately, rationally integrated lifestyle approaches may one day
be used to prevent the development of some breast cancers as well as to restore health in
some cancer patients.

Conclusion
Concomitant molecular and empiric investigations of the relationship between light and
cancer have begun to scratch the surface of this clinically expansive area of research.
Still, clinical applications and shifts in theoretical structure are slow to follow scientific
developments, and there is much room for future investigations to begin clarifying these
ideas and give form to this promising evidence. For example, from a purely clinical
perspective, etiologic theorizing concerning human breast cancer has centered primarily
upon estrogen, its receptors, and the genetic inheritance of traits that influence their
relationship. Currently, a patient’s integrated estrogen exposure over time is perhaps one
of the most exigently debated breast cancer risk factors. Accordingly, the personal
historical elements which are most commonly analyzed in the primary survey of a
patient’s risk and/or prognosis for breast cancer include: age at onset of menarche and
menopause, age of first term pregnancy and number of pregnancies, as well as personal
and family history of pre-menopausal breast cancer 89-91. In contrast, the patient’s
sleep/wake cycle, melatonin rhythm, light history, and work schedule are not typically
considered as being relevant to this cancer risk assessment, in spite of the growing body
of evidence supporting this possibility.
While accumulating evidence points toward potential for the various work schedule and
lifestyle factors to influence tumorigenesis and progression, causality remains elusive and
likely reflects significant variability with physiologic context. For example, it seems that
the pathway by which melatonin influences tumor development and progression is
dependent upon fatty acid availability and metabolism18,70. High fat consumption has not
been consistently correlated with an increased risk of breast cancer in humans92, but
increased constitutional fat content in obese females is correlated with higher levels of
endogenous estrogen, which may, in turn, be the effector that potentiates many
gynecologic neoplasms, such as breast cancer93. Furthermore, dietary constituents have
been correlated with increased risk of other cancers, but the molecular players within this
risk are yet to be consistently identified92,94.
Light exposure, the status of physiologic circadian rhythms, diet95, and exercise habits95,
though recognized as bearing a potential influence on cancer outcome, are less welldefined in their roles in cancer pathophysiology and are consequently often given
subordinate attention in clinical approaches to cancer96. Continued rigorous empirical
inquiry into the physiology and clinical implications of these habitual, integrated aspects
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of life is highly warranted at this time. Ultimately, when the weight of evidence becomes
compelling, the traditions of clinical practice will be adjusted to reflect the relationship
between light and cancer that current evidence suggests.
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